Jessica Chu, PA
Physician Assistant · New Orleans, LANPI 1063076586
Payments from drug & device makers
Across 162 payments — averaging $22.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$642
- Amgen$471
- Dexcom, Inc.$405
- BETA Bionics, Inc.$393
- Lilly USA, LLC$286
- Xeris Pharmaceuticals, Inc.$242
- plus $1K from 22 others
What the payments were for
- Food & beverage$3,665100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 44 | $642 |
| Amgen | 16 | $471 |
| Dexcom, Inc. | 11 | $405 |
| BETA Bionics, Inc. | 10 | $393 |
| Lilly USA, LLC | 13 | $286 |
| Xeris Pharmaceuticals, Inc. | 11 | $242 |
| AstraZeneca(2 entities) | 5 | $202 |
| Sanofi-aventis U.S. LLC | 7 | $151 |
| Corcept Therapeutics | 5 | $114 |
| Merck | 5 | $95 |
| Ascensia Diabetes Care US Inc. | 4 | $67 |
| Bayer | 4 | $63 |
| Amneal Pharmaceuticals LLC | 3 | $61 |
| Medtronic | 4 | $60 |
| Tandem Diabetes Care, Inc. | 2 | $59 |
| Pfizer | 3 | $55 |
| Antares Pharma, Inc. | 3 | $55 |
| Radius Health, Inc. | 1 | $50 |
| IBSA Pharma Inc. | 2 | $27 |
| Theratechnologies Inc. | 1 | $23 |
| Recordati_rare_diseases_inc. | 1 | $23 |
| Insulet Corporation | 1 | $21 |
| Esperion Therapeutics, Inc. | 1 | $19 |
| GSK | 1 | $19 |
| Ascendis Pharma Endocrinology Inc | 1 | $19 |
| Sequel Med Tech, LLC | 1 | $18 |
| Shield Therapeutics Inc | 1 | $14 |
| Cequr Corporation | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- iLet Bionic Pancreas$819
- DEXCOM G6 TRANSMITTER$126
- Ozempic$125
- TEPEZZA$125
- EVENITY$120
- FARXIGA$109
How this compares
$3,665 in reported general payments places this provider in the 90th percentile of 1,246 physician assistant providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 159 | $178,608 |
| OzempicSemaglutide | 111 | $154,661 |
| JardianceEmpagliflozin | 96 | $98,579 |
| TrulicityDulaglutide | 46 | $49,885 |
| KerendiaFinerenone | 23 | $21,871 |
| Tresiba Flextouch U-100Insulin Degludec | 38 | $18,233 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 17 | $15,036 |
| RybelsusSemaglutide | 12 | $11,514 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 13 | $10,156 |
| BaqsimiGlucagon | 13 | $7,484 |
| Novolog FlexpenInsulin Aspart | 34 | $6,425 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 58 | $6,131 |
| Insulin Lispro Kwikpen U-100Insulin Lispro | 18 | $3,599 |
| Nano 2nd Gen Pen NeedlePen Needle, Diabetic | 30 | $2,381 |
| LevoxylLevothyroxine Sodium | 29 | $1,746 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity, Baqsimi | $286 | $235,976218 claims |
| Novo NordiskOzempic, Rybelsus | $642 | $166,175123 claims |
| BayerKerendia | $63 | $21,87123 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $151 | $15,03617 claims |
| PfizerLevoxyl | $55 | $1,74629 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $61 | $22633 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,246 physician assistant providers in Louisiana.
Other physician assistant in New Orleans
- Jefferson OberleNew Orleans$66K
- Jennifer ScheuermannNew Orleans$56K
- Elizabeth ClementNew Orleans$35K
- David GsellNew Orleans$26K
- Nakia BrooksNew Orleans$25K
- Sydney TsenNew Orleans$16K
- Stephanie EscheteNew Orleans$9K
- Rija AmirNew Orleans$7K
- Emily EstopinalNew Orleans$6K
- Shelly EsnardBaton Rouge$141K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.